OptiBiotix Health plc
("OptiBiotix" or the "Company")
15 March 2017
Confirmation of Director appointments to the Board
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that further to the announcements dated 5 January 2017 and 18 January 2017 and completion of the normal regulatory due diligence, Per Rehné and Christina Wood have been appointed to the Board of OptiBiotix. This follows on from their appointments to the Company in January.
As previously announced on 5 January 2017, Per has many years' experience of the food industry, having worked for some of the world's leading food companies including most recently Cornelius Group plc where he acted as European Director of Health and Nutrition.
As announced on 18 January 2017, Christina has 25 years' sales experience within the food, nutrition, and nutraceuticals industry. As the owner and CEO of Confoco, a supplier of high quality food ingredients worldwide, Christina grew the business from £1m to £11m sales by obtaining strategic supplier status with multiple global corporates including Nestlé, Danone, and Heinz.
Christina Mary Wood
Pursuant to Rule 17 and Schedule Two (g) of the AIM Rules, the following information is disclosed in respect of Christina Mary Wood (aged 57):
Current Appointments |
Appointments in the last 5 years |
- |
John Morley (Importers) Limited |
|
Confoco International Limited |
There is no other information regarding Christina Wood required to be disclosed under the AIM Rules.
Per Rehné
Pursuant to Rule 17 and Schedule Two (g) of the AIM Rules, the following information is disclosed in respect of Per Rehné (aged 47):
Current Appointments |
Appointments in the last 5 years |
- |
Cornelius Group Plc |
|
Cornelius Nordic APS |
|
Custom Fiber Europe N.V. |
|
Rehné Consult 2014 ApS |
|
DJAP Holdings ApS |
|
K/S Welford Place |
|
Welford Place Komplementar ApS |
Mr Rehné was a director of DJAP Holdings ApS which was placed into liquidation in October 2016 having been dormant for a period of two years and subsequently in November 2016 was placed in insolvency procedures due to an outstanding balance of circa £2,000.
Mr Rehné was a director of K/S Welford Place between May 2010 and March 2016. In March 2016, the company was placed into voluntary liquidation.
Mr Rehné was a director of Welford Place Komplementar ApS between May 2010 and March 2016. In March 2016, the Company was placed into voluntary liquidation and dissolved thereafter.
There is no other information regarding Per Rehné required to be disclosed under the AIM Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information:
OptiBiotix Health plc |
www.optibiotix.com |
Stephen O'Hara, Chief Executive |
Contact via Walbrook below |
|
|
Cairn Financial Advisers LLP |
Tel: 020 7213 0880 |
Liam Murray / Jo Turner |
|
|
|
finnCap (Broker) |
Tel: 020 7220 0500 |
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance) |
|
Tony Quirke (Corporate Broking) |
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
Anna Dunphy |
Mob: 07876 741 001 |
|
|
|
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
